Effect of GLP-1 receptor agonists on body composition

Oct 12, 2025Current opinion in endocrinology, diabetes, and obesity

How GLP-1 receptor agonists affect body fat and muscle

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Up to 85% of individuals with type 2 diabetes mellitus (T2DM) are obese, presenting significant treatment challenges.

GLP-1 receptor agonists (GLP-1RAs) lead to significant fat mass loss, particularly in visceral fat.
There are modest proportional declines in lean body mass (LBM), but relative preservation or improvement of LBM is observed.
Resting energy expenditure (REE) is generally maintained, with some studies indicating increases during extended treatment.
GLP-1RAs enhance metabolic health in both diabetic and nondiabetic individuals without accelerating muscle loss.
Evidence from rodent studies suggests protective muscle effects through anti-inflammatory and muscle-building mechanisms.
Weight regain after stopping treatment occurs mainly as fat mass, underscoring the need for ongoing therapy or lifestyle support.

AI simplified

PURPOSE OF REVIEW: Obesity is present in up to 85% of individuals with type 2 diabetes mellitus (T2DM) and poses a major therapeutic challenge. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for T2DM, are now widely used for obesity management and increasingly recognized for their impact on body composition beyond weight reduction. This review summarizes evidence on the effects of GLP-1RAs, particularly semaglutide and liraglutide, on fat mass, lean body mass (LBM), visceral adipose tissue (VAT), and resting energy expenditure (REE).

RECENT FINDINGS: Clinical trials and meta-analyses show GLP-1RAs achieve marked fat mass loss, preferentially reducing VAT, with modest proportional declines in LBM. Despite reductions in absolute LBM, relative preservation or improvement is observed, and REE is largely maintained, with some reports of increases during prolonged therapy. In both diabetic and nondiabetic populations, GLP-1RAs improve metabolic health without accelerating sarcopenia. Rodent data support protective muscle effects through anti-inflammatory and myogenic mechanisms. Withdrawal, however, predictably results in weight regain, primarily as fat mass, highlighting the importance of continued therapy or supportive lifestyle strategies.

SUMMARY: GLP-1RAs confer favourable body composition outcomes, with clinical implications for obesity, sarcopenic obesity, and broader metabolic disease management.

Full Text

Full text is available at the source.

View full text ↗

Effect of GLP-1 receptor agonists on body composition

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief